{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Safety assessments will be evaluated as the proportion of patients experiencing the following: treatment-related grade 3 or higher toxicity (hematologic and nonhematologic) and treatment-related death.","groups":[{"description":"Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d\n\nMelphalan: IV over 30 min, Day 1 q28d\n\nVelcade®: IV bolus, Day 1, 4, 8, 11 q28d\n\nDose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2\n\nDose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2\n\nDose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2\n\nDose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2","id":"OG000","title":"Doxil® + Melphalan + Velcade (DMV)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only data for Phase 1, Cohort 1 DLT was collected","reportingStatus":"POSTED","timeFrame":"Up to 2 cycles of treatment, approximately 56 days","title":"Number of Participants With Dose Limiting Toxicities (DLT) (Phase 1)","type":"PRIMARY","unitOfMeasure":"Participants"}